Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational cell therapy consists of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and is being developed by the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital) for the treatment of stage II-III knee osteoarthritis. The therapy is administered via arthroscopy-mediated intra-articular injection. hUC-MSCs are multipotent cells that facilitate joint repair through several mechanisms: they can differentiate into chondrocytes to promote cartilage regeneration, secrete various growth factors and cytokines to support tissue repair, and provide immunomodulatory effects that reduce inflammation within the osteoarthritic joint environment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells (First Affiliated Hospital of Wannan Medical College).